Research programme: respiratory tract disorder therapeutics - Chiesi Farmaceutici

Drug Profile

Research programme: respiratory tract disorder therapeutics - Chiesi Farmaceutici

Alternative Names: CHF-6366

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Corticosteroids
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Leucocyte elastase inhibitors; Muscarinic receptor antagonists; P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma; Bronchiectasis; Bronchopulmonary dysplasia; Chronic obstructive pulmonary disease; Cystic fibrosis

Most Recent Events

  • 13 Sep 2017 Pharmacodynamics data from a preclinical trial in Chronic obstructive pulmonary disease presented at the 27th Annual Congress of the European Respiratory Society (ERS-2017)
  • 28 Jun 2016 Preclinical development is ongoing for Asthma, Cystic Fibrosis, Chronic obstructive pulmonary disease and Bronchiectasis in Italy (Chiesi Farmaceutici pipeline, June 2016)
  • 13 Jan 2016 Preclinical trials in Bronchopulmonary dysplasia in Italy (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top